,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['dance', 'bcsm', 'breast', 'destiny-breast04']
 practice-changing results from destiny-breast04 were presented at #asco22 today! ild/pneumonitis rate of 12%. excellent time to review guidance on the diagnosis &amp; management of t-dxd-related ild/pneumonitis by et al. #bcsm 
Chief Heme/Onc Education Fellow @MDAndersonNews | Alum of @dukeu @muschealth @vumchealth | Interest in #meded ??#cancer #lcsm | Tweets my own ? medical advice